Norway's national system, launched in 2013, for deciding which new treatments public hospitals may use. Under it, as a rule, a new hospital cancer medicine or indication cannot be prescribed until its Decision Forum, the four regional health authorities' chief executives, says yes.
Nye metoder is the national system of managed introduction of new methods in Norway's specialist health care service, launched in 2013, and the four regional health authorities (South-Eastern, Western, Northern and Central Norway) are responsible for it. Its English page explains that, as a general rule, new medicinal products and indications cannot be prescribed in the specialist health services until the Decision Forum (Beslutningsforum) has made a positive decision; once an assessment has been commissioned, a medicine may be used under an exemption scheme if specific requirements are met.
An Ordering Forum of the four regional medical directors and two delegates from the Directorate of Health decides which assessments to commission. The Norwegian Medical Products Agency assesses medicines and medical devices and the Norwegian Institute of Public Health assesses procedures and other interventions; the Institute says national assessments carry no direct recommendation, and the priority criteria used in Norway are benefit, resource use and severity. After a single technology assessment, the Norwegian Hospital Procurement Trust (Sykehusinnkjøp) negotiates the price, and the Decision Forum, the four regional chief executives, decides. Hospitals also run local mini-HTAs. Its secretariat's contact address is at the South-Eastern Norway Regional Health Authority; the coordinates are an approximate Oslo city point.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/